Published on March 16, 2016
March 16, 2016
The amount of material the major multiple sclerosis organizations have on vitamin D, latitude and MS is colossal. MS organizations are funding research, but it may not adequately represent vitamin D’s potential. Many studies include bolus dosing, instead of the daily dosing necessary to boost the immune system. Every study measures 25(OH)D, but they are still grouping results based on input groups (i.e. 1000 IU/day) and not by vitamin D level. Many of these studies are scared to dose with “toxic” levels of vitamin D, and as Dr. Coimbra points out – MS patients seem to be resistant to processing vitamin D. Many of the trials will not elicit a big enough change in vitamin D status to effect a change in health status.
But… using our HYLION methodology we could change that. We could do a population-study on the groups that are taking high levels of vitamin D with success. How is it working? Are the patients still relapsing? Is their mobility and pain improving? Is their calcium too high? Too low?
My hope is that by this time next year we can report on a study, which will have been funded by a major MS organization, showing the efficacy of vitamin D and MS. Perhaps even, as Dr. Garland says in his editorial below, a new standard of care for healthy children – to prevent MS – or as the National MS Society says – “a world free of MS.”